乙型肝炎后肝硬化治疗中核苷类药物的效果分析

Application of nucleoside drugs in the treatment of posthepatitis B cirrhosis

目的探讨乙型肝炎后肝硬化治疗中核苷类药物的应用效果。方法选取2016年6月至2018年6月本院收治的82例乙型肝炎后肝硬化患者作为研究对象,根据不同治疗方案分为对照组与观察组,各41例。对照组采用常规治疗,观察组采用核苷类药物治疗,6个月后比较两组患者的血清乙肝病毒(HBV-DNA)变化情况、乙肝e抗原(HBeAg)转阴率和丙氨酸基转移酶(ALT)复常率及不良反应发生率。结果治疗前两组HBV-DNA比较差异无统计学意义;治疗后观察组HBV-DNA(3.16±1.05)(log10 copies/mL)明显低于对照组的(4.25±1.26)(log10 copies/mL);观察组ALT复常率、HBeAg转阴率(60.98%、46.34%)明显高于对照组(31.71%、19.51%)(P<0.05);观察组不良反应发生率为7.32%,明显低于对照组的24.39%(P<0.05)。结论乙型肝炎后肝硬化治疗中应用核苷类药物可有效降低病毒荷载,提高治疗效果,减少不良反应。

Objective To investigate the application effect of nucleoside drugs in the treatment of post-hepatitis B cirrhosis.Methods 82 patients with post-hepatitis B cirrhosis admitted to our hospital were enrolled in this study.They were divided into the control group and the observation group according to different treatment options,with 41 cases in each group.The control group was treated with conventional therapy,and the observation group was treated with nucleoside drugs.After 6 months,the changes of serum hepatitis B virus(HBV-DNA),hepatitis B e antigen(HBeAg)conversion rate and alanine transferase(ALT)reversion rate and the incidence of adverse reactions were compared between two groups.Results There was no significant difference in HBV-DNA between the two groups before treatment.The HBV-DNA(3.16±1.05)(log10 copies/mL)in the observation group was significantly lower than that in the control group(4.25±1.26)(log10 copies/mL).The ALT recurrence rate and HBeAg conversion rate(60.98%,46.34%)in the observation group were significantly higher than those in the control group(31.71%,19.51%)(P<0.05).The incidence of adverse reactions in the observation group(7.32%)was significantly lower than the control group(24.39%)(P<0.05).Conclusion The use of nucleoside drugs in the treatment of post-hepatitis B cirrhosis can effectively reduce the viral load,improve the therapeutic effect and reduce adverse reactions.